PET Trial For Alzheimer’s Opens Door For CMS-Backed Research – Phurrough
This article was originally published in The Gray Sheet
Executive Summary
CMS' decision to fund the full costs of clinical trials assessing positron emission tomography to diagnose Alzheimer's disease marks a step toward the establishment of trial coverage as a viable national coverage decision alternative for the agency